Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

was developed by Shire to give patients more choice in how they take their phosphate binder. Submissions for national marketing authorisations of FOSRENOL in oral powder form have been made to Sweden and the other 27 European markets, with the first national approvals anticipated in Q2 2012.

Pipeline


REPLAGAL - for the treatment of Fabry disease

  • On March 14, 2012 Shire announced that it had withdrawn its Biologics License Application ("BLA") for REPLAGAL with the FDA. In 2009, and again in 2011, the FDA encouraged Shire to submit an application for the approval of REPLAGAL in the US. These discussions led Shire to file a BLA in November 2011 in anticipation of a quick review process and eventual approval. Recent interactions with the FDA in Q1 2012 led Shire to believe that the FDA would require additional controlled trials for approval. No concerns over the product's safety profile were raised by the FDA. Shire has concluded that the likely additional studies would cause a significant delay, and an approval of REPLAGAL for US patients would only be possible in the distant future. Shire therefore decided to withdraw its BLA. Patients currently treated with REPLAGAL in the US under treatment access programs will be transitioned off REPLAGAL therapy by June 30, 2012.

SPD476, MMX® mesalamine - for the treatment of diverticular disease

  • On March 30, 2012 Shire announced top-line results of the PREVENT2 trial, a Phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis. The study did not meet the primary endpoint in reducing the rate of recurrence of diverticulitis over a two year treatment period. Shire will continue to analyze these data and those of the second study, PREVENT1, which was similar in design to PREVENT2 and will report later in the year. Although the
    '/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... second quarter ending June 30, 2015. ... We are excited to be near the completion of ... with topline results expected in the fourth quarter," stated ... Inc. "Translarna is now commercially available in 12 countries ...
(Date:7/30/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... regarding the notice it received on May 21, 2015 ... the Company was below certain of the Exchange,s continued ... 1101 of the NYSE MKT Company Guide, due to ...
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Cepheid (NASDAQ: CPHD) ... Officer, received the Ernst & Young Entrepreneur Of The ... category. According to Ernst & Young LLP, the award ... in such areas as innovation, financial performance and personal ...
... 28, 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: ... Russell 3000®, Russell 2000® and Russell Global Indexes posted by ...   Annual reconstitution of Russell,s U.S. indexes captures ... May, ranking them by total market capitalization. Membership in the ...
Cached Medicine Technology:Cepheid CEO John Bishop Named Ernst & Young Entrepreneur Of The Year® 2011 Northern California Award winner 2Cepheid CEO John Bishop Named Ernst & Young Entrepreneur Of The Year® 2011 Northern California Award winner 3Cell Therapeutics Added to Russell 3000®, Russell 2000® and Russell Global Indexes 2Cell Therapeutics Added to Russell 3000®, Russell 2000® and Russell Global Indexes 3
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca Life ... the go. With no water needed, the refreshing berry-flavored tablets are the perfect ... get the natural ingredients that may help with body detoxification, protection and hydration,” ...
(Date:7/30/2015)... Los Angeles, CA (PRWEB) , ... July 30, 2015 , ... ... driverless cars on an upcoming dedicated web site. As discussed in a June 8, ... of the minor collisions reported so far have been caused by its computer-driven cars, ...
(Date:7/30/2015)... CA (PRWEB) , ... July ... ... recently released a video, “Beachside Nursing Center,” to announce its position as ... five-star ratings. Beachside's administrator and staff members support the CMS rating system, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a ... That Increases Training Capability , World renown body weight trainer, Paul Ziachik, ... ), that dramatically increases a person’s training capability. , The American College of ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston Web Marketing ... Summit. Google Partners is the platform for search marketing agencies to communicate with ... tools necessary to run successful search marketing campaigns. Google Partners also affords businesses ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2
... (Nasdaq: KNDL ) announced today that it ... the market closes on Wednesday, May 6, 2009. The ... webcast on Thursday, May 7 at 8:30 a.m. Eastern ... http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO ) Conference ...
... Pharmacy benefit manager Prime Therapeutics (Prime) announced today its ... Heart Walk. Prime is participating both as a sponsor ... 11 Blue Cross and Blue Shield Plans. Prime provides ... a deep commitment to improving the health of members," ...
... in 2017 for the Treatment of STEMI with ... from Decision ResourcesWALTHAM, Mass., April 23 Decision ... advisory firms for pharmaceutical and healthcare issues, finds ... mortality as the attribute that most influences their ...
... Expansion with Plans to Triple Overall Lab Capacity; Builds ... PLUS Diagnostics, a leading anatomic pathology company, announced today ... opening of a West Coast laboratory in Orange County, ... into a new laboratory in Union, New Jersey to ...
... InfoLogix, Inc. (Nasdaq: ... of enterprise mobility solutions for the healthcare and ... into an agreement with Gwinnett Medical Center ... suburban Atlanta, to deploy a next-generation, handheld Care ...
... ,high-glycemic, carbs, researchers say , , THURSDAY, April 23 (HealthDay News) ... workout may influence how many calories you burn during your ... rich in carbohydrates that do not cause a spike in ... burned 50 percent more fat during a post-breakfast workout than ...
Cached Medicine News:Health News:Kendle Announces First Quarter 2009 Earnings Conference Call and Webcast 2Health News:For ST-Elevation Myocardial Infarction (STEMI), Interviewed Experts Indicate That The Medicines Company's Angiomax/Angiox Has Efficacy Advantages Over Sales-Leading ReoPro 2Health News:For ST-Elevation Myocardial Infarction (STEMI), Interviewed Experts Indicate That The Medicines Company's Angiomax/Angiox Has Efficacy Advantages Over Sales-Leading ReoPro 3Health News:PLUS Diagnostics Opens West Coast Laboratory to Support Increased Demand for Anatomic Pathology Services 2Health News:PLUS Diagnostics Opens West Coast Laboratory to Support Increased Demand for Anatomic Pathology Services 3Health News:InfoLogix Selected by Gwinnett Medical Center to Transform Clinical Care Through Next-Generation Mobile Communications Solution 2Health News:InfoLogix Selected by Gwinnett Medical Center to Transform Clinical Care Through Next-Generation Mobile Communications Solution 3Health News:A Pre-Workout Meal to Help You Burn Fat 2Health News:A Pre-Workout Meal to Help You Burn Fat 3
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
... system uses prolene as thread-guide reducing time and ... Probe is inserted into the nasolacrimal duct and ... The probe is then withdrawn leaving the polypropylene ... diam silicone tubing into place. Newly coated with ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... conforms to natural anatomy of the ... on disposable inserter/dilator instrument for ease ... The Micro-Large plugs feature the unique ... shape of the eyelid. The slightly ...
Medicine Products: